1. Home
  2. ASIC vs PHAT Comparison

ASIC vs PHAT Comparison

Compare ASIC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASIC

Ategrity Specialty Insurance Company Holdings

HOLD

Current Price

$19.86

Market Cap

930.6M

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$12.04

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASIC
PHAT
Founded
2018
2018
Country
United States
United States
Employees
203
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
930.6M
894.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ASIC
PHAT
Price
$19.86
$12.04
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$26.75
$19.83
AVG Volume (30 Days)
63.0K
1.4M
Earning Date
04-29-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
$34.21
$93.04
Revenue Next Year
$34.65
$58.91
P/E Ratio
$98.60
N/A
Revenue Growth
N/A
216.93
52 Week Low
$16.35
$3.69
52 Week High
$23.88
$18.31

Technical Indicators

Market Signals
Indicator
ASIC
PHAT
Relative Strength Index (RSI) 51.13 48.15
Support Level $17.16 $10.38
Resistance Level $21.21 $12.52
Average True Range (ATR) 1.01 0.98
MACD -0.01 -0.01
Stochastic Oscillator 27.96 61.97

Price Performance

Historical Comparison
ASIC
PHAT

About ASIC Ategrity Specialty Insurance Company Holdings

Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: